Hyperparathyroidism malady

Wikipedia: Hyperparathyroidism is overactivity of the parathyroid glands resulting in excess production of...⁴⁴ more...

MalaCards: Hyperparathyroidism is related to primary hyperparathyroidism and hyperparathyroidism-jaw tumor syndrome. An important gene associated with Hyperparathyroidism is CDC73 (cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)), and among its related pathways are Transcription Role of VDR in regulation of genes involved in osteoporosis and Transcription_Role of VDR in regulation of genes involved in osteoporosis. The drugs calcitriol and dihydrotachysterol and the compounds 25-hydroxyvitamin d and carbohydrates have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, whole blood and skeletal muscle, and related mouse phenotypes are growth/size and skeleton.

Aliases & Descriptions:

hyperparathyroidism 6 7 8 32 43

Disease types for hyperparathyroidism family:

hyperparathyroidism 3

Diseases related to hyperparathyroidism by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1007)

id	Related Disease	Score	Top Affiliating Genes
1	primary hyperparathyroidism	39.2	RET, GCM2, VDR, PBX1, BGLAP, PAX5
2	hyperparathyroidism-jaw tumor syndrome	36.2	RET, CDC73, MEN1, CCND1, CASR
3	familial isolated hyperparathyroidism	35.8	RET, CDC73, MEN1, CASR, PTH, GAST
4	hypocalciuric hypercalcemia	34.1	CASR, CALCA, PTH, SPG7, NR1I3, PRKAR1A
5	hypercalcemia	33.6	KL, GC, VDR, BGLAP, SCT, CHGA
6	familial hypocalciuric hypercalcemia	33.3	CASR, SPG7, NR1I3, CXADR
7	secondary hyperparathyroidism of renal origin	32.7	VDR, BMP7, BGLAP, B2M, CD36, FGF23
8	parathyroid carcinoma	31.7	CDC73, MEN1, CASR, PTH, CXADR
9	hyperparathyroidism, neonatal severe primary	31.6	CASR, NR1I3, PRKAR1A, CXADR
10	osteitis fibrosa	31.2	BGLAP, B2M, ALPP, GNAS, CASR, CALCA
11	hypocalcemia	30.9	GCM2, VDR, BGLAP, CD36, FGF23, IAPP
12	osteomalacia	30.8	KL, GC, VDR, BGLAP, CD36, FGF23
13	multiple endocrine neoplasia	30.7	RET, VIP, BRCA2, PBX1, SCT, CHGA
14	rickets	30.6	GC, VDR, BGLAP, LEP, CD36, INS
15	parathyroid adenoma	30.5	RET, PCNA, GCM2, VIP, VDR, BGLAP
16	multiple endocrine neoplasia type 2a	29.9	RET, CDC73, MEN1, CALCA, PTH, NF1
17	humoral hypercalcemia of malignancy	29.7	BGLAP, FGF23, CASR, TNF, TNFSF11, PTH1R
18	nephrocalcinosis	29.1	LRP2, ALB, CASR, NR1I3, SLC34A1
19	uremia	28.9	RET, VWF, SERPINE1, VIP, VDR, LEP
20	hypoparathyroidism	28.7	RET, GCM2, VDR, BGLAP, INS, FGF23
21	renal osteodystrophy	28.7	VDR, BMP7, BGLAP, LEP, B2M, CD36
22	parathyroid disorders	28.6	RET, CDC73, MEN1, CASR, PTH, PTHLH
23	ossifying fibroma	28.1	BGLAP, CDC73, GNAS, RUNX2
24	fibrous dysplasia	28.1	BGLAP, CD36, FGF23, IL6, IBSP, ALPP
25	breast cancer	28.0	BRCA2, VDR, IL6, CCND1, TP53, TNF
26	neurofibromatosis	27.9	RET, KITLG, BRCA2, MEN1, GHR, SST
27	mccune albright syndrome	27.8	GNAS, GH1, PRL
28	goiter	27.8	RET, SELE, BGLAP, LEP, INS, FGFR1
29	liver cirrhosis	27.5	VIP, SCT, GPT, IGFBP3, ALB, ALPP
30	peptic ulcer	27.2	SCT, FGF2, MEN1, IL2, IL6, CCK
31	follicular adenoma	27.2	RET, MEN1, IL6R, PTHLH, KLK3, TG
32	papillary thyroid carcinoma	27.1	RET, BAX, FGFR1, MEN1, CCND1, IBSP
33	osteosclerosis	27.1	LRP5, BGLAP, IGF2, IGFBP2, ALPP, TNFRSF11B
34	arterial calcification	27.0	VWF, GC, SELE, VDR, BGLAP, LEP
35	insulinoma	26.8	VIP, PBX1, SCG5, SCT, CHGA, CDKN1A
36	sickle cell disease	26.5	KL, VWF, SELE, SERPINE1, BGLAP, B2M
37	amyloidosis	26.4	RET, VWF, BGLAP, B2M, INS, IL6
38	hemangioma	26.1	RET, KITLG, VWF, SELE, CHGA, FGF2
39	aldosteronism	26.0	KL, SERPINE1, VIP, BMP7, KCNQ1, CHGA
40	hyperthyroidism	25.9	KITLG, VWF, SELE, SERPINE1, VDR, BGLAP
41	osteoporosis	25.9	LRP5, KL, GC, GCM2, SELE, VDR
42	thymoma	25.6	VIP, CHGA, LBR, B2M, CDKN1A, IL2
43	obesity, association with	25.6	VWF, SERPINE1, LEP, INS, IL6, GPT
44	mediastinitis	25.3	PCNA, SELE, PAX5, IL6, ALPP, CALCA
45	pheochromocytoma	25.1	RET, SERPINE1, VIP, SCG5, SCT, LEP
46	anemia	24.3	SGCB, KITLG, VWF, PCNA, SELE, BRCA2
47	papilloma	24.0	RET, PCNA, BRCA2, BAX, CDKN1A, CD36
48	duodenitis	23.5	KITLG, PCNA, VIP, VDR, SCG5, SCT
49	blindness	23.4	LRP5, VWF, SELE, SERPINE1, VIP, VDR
50	thyroid cancer	22.9	LRP2, RET, PCNA, GCM2, BGLAP, CHGA

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 calcitriol, cod liver oil [va product], dihydrotachysterol, doxercalciferol, paricalcitol

MalaCards organs/tissues related to hyperparathyroidism:

²²

MGI Mouse Phenotypes related to hyperparathyroidism:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size phenotype	MP:0005378	INF	LRP2, KL, RET, SGCB, KITLG, SELE
2	skeleton phenotype	MP:0005390	INF	LRP2, KITLG, GC, GCM2, BRCA2, VDR
3	limbs/digits/tail phenotype	MP:0005371	INF	LRP5, KL, RET, KITLG, BRCA2, VDR
4	respiratory system phenotype	MP:0005388	10.3	LRP2, KL, RET, SCG5, CFTR, CDC73
5	pigmentation phenotype	MP:0001186	9.1	LRP5, KITLG, BMP7, CDKN1B, CASR, TP53
6	endocrine/exocrine gland phenotype	MP:0005379	9.1	LRP2, LRP5, KL, RET, GCM2, BRCA2
7	hematopoietic system phenotype	MP:0005397	9.0	PCNA, BRCA2, CDKN1A, CDKN2C, CDC73, FGF2
8	no phenotypic analysis	MP:0003012	8.1	LRP2, RET, PCNA, LBR, CEBPB, CDKN1B
9	tumorigenesis	MP:0002006	7.8	RET, KITLG, SERPINE1, BRCA2, LEP, B2M
10	adipose tissue phenotype	MP:0005375	7.5	KL, SERPINE1, SCG5, LEP, LBR, CEBPB
11	vision/eye phenotype	MP:0005391	6.5	LRP2, LRP5, KITLG, SELE, BMP7, LEP
12	muscle phenotype	MP:0005369	6.0	KL, RET, SGCB, LEP, BAX, CEBPB
13	reproductive system phenotype	MP:0005389	INF	RET, VIP, BRCA2, VDR, BMP7,
14	behavior/neurological phenotype	MP:0005386	INF	LRP2, LRP5, KL, SELE, VIP, BRCA2
15	normal phenotype	MP:0002873	INF	LRP5, RET, SELE, VIP, BRCA2, BMP7
16	embryogenesis phenotype	MP:0005380	INF	LRP5, RET, GCM2, BRCA2, , CDC73
17	cardiovascular system phenotype	MP:0005385	INF	LRP5, KL, RET, SGCB, KITLG, VWF
18	mortality/aging	MP:0010768	INF	LRP5, KL, RET, KITLG, VWF, SELE
19	cellular phenotype	MP:0005384	INF	LRP2, LRP5, KL, RET, KITLG, VWF
20	immune system phenotype	MP:0005387	INF	LRP5, KL, SGCB, VWF, BRCA2, VDR
21	homeostasis/metabolism phenotype	MP:0005376	INF	LRP2, LRP5, KL, RET, KITLG, VWF
22	craniofacial phenotype	MP:0005382	INF	LRP2, LRP5, KITLG, GCM2, , LBR
23	nervous system phenotype	MP:0003631	INF	LRP5, KL, KITLG, VWF, GCM2, BMP7
24	digestive/alimentary phenotype	MP:0005381	INF	LRP2, KL, RET, KITLG, VWF, BRCA2
25	integument phenotype	MP:0010771	INF	KL, KITLG, BRCA2, , SCG5, LBR
26	hearing/vestibular/ear phenotype	MP:0005377	INF	LRP2, KITLG, VDR, BMP7, , PAX5
27	liver/biliary system phenotype	MP:0005370	INF	LRP5, , SCG5, CFTR, CD36, CDC73
28	renal/urinary system phenotype	MP:0005367	INF	LRP2, KL, RET, GCM2, BMP7,
29	other phenotype	MP:0005395	INF	KL, , IL2, CASR, CAPN2, NOS3

Articles related to hyperparathyroidism:

(show top 50)    (show all 513)

id	Title	Authors	Year	Affiliating Genes
1	Endothelial activation markers soluble E-selectin and von Willebrand factor in primary hyperparathyroidism. (21471547)	Lumachi F.... Fallo F.	2011	VWF, SELE
2	Hyperparathyroidism due to eutopic PTH secretion from an ectopic intrathymic parathyroid cyst. (21881376)	Hoi W.H.... Tay J.C.	2011	PTH
3	Role of multifunctional cell cycle modulators in adva nced secondary hyperparathyroidism. (21595849)	Sato T.... Tominaga Y.	2011	CEBPB
4	Hyperparathyroidism-jaw tumor syndrome: a case report . (19942209)	Rekik N.... Abid M.	2010	CDC73
5	Involvement of alpha-klotho and fibroblast growth fac tor receptor in the development of secondary hyperparathyroidism. (20068287)	Kumata C.... Akizawa T.	2010	FGFR1, KL
6	Roles of calcium-sensing receptor and vitamin d recep tor in the pathophysiology of secondary hyperparathyroidism. (20303786)	McCann L.M.... Beto J.	2010	VDR, CASR, NR1I3
7	Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis. (18045826)	DA-ez J.J.... Selgas R.	2008	VIP, CCK, GHRL
8	The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. (18178780)	Messa P.... Locatelli F.	2008	CASR
9	High prevalence of hypovitaminosis D and secondary hyperparathyroidism in elders living in nonprofit homes in South Brazil. (18401764)	Scalco R.... Furlanetto T.W.	2008	ALB
10	Primary hyperparathyroidism: a current perspective. (18684024)	DeLellis R.A.... Mangray S.	2008	CCND1, CDC73
11	Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. (18682507)	Bjorklund P.... Larsson T.E.	2008	KL
12	Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. (19092296)	Cetani F.... Marcocci C.	2008	CDC73
13	Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). (18587716)	Cannata-AndA-a J.B.... Benedik M.	2008	PTH
14	Normocalcemic, subclinical, asymptomatic primary hyperparathyroidism in patients with goiter or papillary thyroid cancer--preliminary report. Normocalcemic primary hyperparathyroidism and thyroid pathology. (17966885)	NiedA_wiecki S.... Pomorski L.	2007	SLPI
15	Pancreatitis in primary hyperparathyroidism-related hypercalcaemia is not associated with mutations in the CASR gene. (17853337)	Felderbauer P.... Schmidt W.E.	2007	CASR, NR1I3
16	Mutations in genes causing human familial isolated hyperparathyroidism do not account for hyperparathyroidism in Keeshond dogs. (17158076)	Skelly B.J.... Franklin R.J.	2007	CASR, MEN1
17	Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells. (17911347)	Brunner S.... Franz W.M.	2007	KITLG, CSF3, CXCL12
18	Hyperparathyroidism-jaw tumor syndrome. A hereditary form of primary hyperparathyroidism with parathyroid carcinoma (17583828)	Raue F.... Frank-Raue K.	2007	CDC73
19	Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. (17161223)	Delfini E.... Letizia C.	2007	LEP, ADIPOQ
20	Body composition changes in haemodialysis patients wi th secondary hyperparathyroidism after parathyroidectomy measured by convention al and vector bioimpedance analysis. (16469153)	Peters B.S.... Martini L.A.	2006	ALB
21	Dissimilar PTH, gastrin, and calcitonin responses to oral calcium and peptones in hypocalciuric hypercalcemia, primary hyperparathyroidism, and normal subjects: a useful tool for differential diagnosis. (16491288)	Bevilacqua M.... Barbagallo M.	2006	CALCA, CASR, PTH
22	Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. (16817812)	Mizusawa N.... Yoshimoto K.	2006	CASR, MEN1, CDC73
23	Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. (16105030)	D'Amour P.... Zahradnik R.J.	2005	PTH
24	The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve. (15642800)	Bas S.... Rodriguez M.	2005	CXADR
25	Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism (15526839)	Matuszkiewicz-RowiA8ska J.... Ostrowski K.	2004	CALCA, PTH
26	Apoptosis and P53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism. (15188026)	Szende B.... Kopper L.	2004	TP53, BAX
27	Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. (14715834)	Simonds W.F.... Marx S.J.	2004	CASR, CDC73
28	Age-related femoral bone loss in men: evidence for hyperparathyroidism and insulin-like growth factor-1 deficiency. (15699527)	Blain H.... Jeandel C.	2004	PTH
29	Pathogenesis of refractory secondary hyperparathyroidism. (11982830)	Rodriguez M.... Almaden Y.	2002	VDR
30	Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. (12414855)	Nakchbandi I.A.... Insogna K.	2002	IL6, IL6R
31	Clinical effect of intravenous calcitriol administrat ion on secondary hyperparathyroidism. A double-blind study among 4 doses. (11961400)	Koshikawa S.... Suzuki M.	2002	ALB
32	Primary hyperparathyroidism, C-cell hyperplasia and papillary thyroid carcinoma in a patient with RET germline polymorphism S836S. (12410354)	Brauckhoff M.... Dralle H.	2002	RET, CALCA
33	Bisphosphonates and primary hyperparathyroidism. (12412793)	Rodan G.A.	2002	PTHLH
34	Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. (11703583)	VAolimAoki S.... Farnebo L.O.	2001	VDR, CASR, NR1I3
35	Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. (11158862)	Slatopolsky E.... Dusso A.	2001	EGFR, VDR, TGFA
36	Pre- and postoperative bone metabolism of primary hyperparathyroidism. (10915001)	Suzuki S.... Takenoshita S.	2000	SLPI
37	Association between parathyroid hormone (PTH)/PTH-related peptide receptor gene polymorphism and the extent of bone mass reduction in primary hyperparathyroidism. (11014383)	Kanzawa M.... Chihara K.	2000	ALPP, PTH, PTH1R
38	Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. (9626148)	Teh B.T.... Larsson C.	1998	MEN1
39	Persistent secondary hyperparathyroidism after renal transplantation. (9844148)	Messa P.... Mioni G.	1998	VDR
40	Two novel missense mutations in calcium-sensing receptor gene associated with neonatal severe hyperparathyroidism. (9253359)	Kobayashi M.... Seino Y.	1997	CASR
41	Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene. (9217223)	Cole D.E.... Hendy G.N.	1997	CASR
42	In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. (9011580)	Bai M.... Steinmann B.	1997	NR1I3
43	Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen. (8678946)	Katagiri M.... Harada T.	1996	CD36
44	Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. (8675600)	Pausova Z.... Hendy G.N.	1996	RET
45	More on hyperparathyroidism and the vitamin D receptor. (8898730)	Tsukamoto Y.... Tazawa H.	1996	VDR
46	Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. (8675635)	Pearce S.H.S.... Thakker R.V.	1995	CASR, NR1I3
47	Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia (7752492)	Morio K.... Koide K.	1995	CALCA
48	Renal osteodystrophy with hyperparathyroidism: the diagnostic value of intact parathormone, alkaline phosphatase, osteocalcin and procollagen. (7865545)	Rubini G.... D'Addabbo A.	1994	SLPI, BGLAP
49	Familial isolated primary hyperparathyroidism. (7955451)	Kassem M.... Kruse T.A.	1994	CALCA, PRL
50	Expression of chromogranin-A messenger ribonucleic acid in parathyroid tissue from patients with primary hyperparathyroidism. (2347900)	Levine M.A.... Ahn T.G.	1990	CHGA

Genes related to hyperparathyroidism according to GeneCards:

(show top 50)    (show all 134)

id	Symbol	Description	Score	GeneCards Section Context
1	CDC73	cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)	11.1	Publications, Orthologs, Summaries, Aliases & Descriptions
2	CASR	calcium-sensing receptor	11.1	Summaries, Publications
3	NR1I3	nuclear receptor subfamily 1, group I, member 3	11.1	Summaries, Publications
4	VDR	vitamin D (1,25- dihydroxyvitamin D3) receptor	11.1	Publications, Summaries
5	HRPT3	Hyperparathyroidism 3	11.0	Aliases & Descriptions
6	HRPT1	hyperparathyroidism 1	11.0	Aliases & Descriptions
7	HPRHP	Hypophosphatemic rickets and hyperparathyroidism	11.0	Aliases & Descriptions
8	MEN1	multiple endocrine neoplasia I	11.0	Functions, Publications
9	PTH	parathyroid hormone	11.0	Publications
10	FGF23	fibroblast growth factor 23	11.0	Publications
11	CXADR	coxsackie virus and adenovirus receptor	11.0	Publications
12	CYP27B1	cytochrome P450, family 27, subfamily B, polypeptide 1	11.0	Publications
13	BGLAP	bone gamma-carboxyglutamate (gla) protein	11.0	Publications
14	GAST	gastrin	11.0	Publications
15	RET	ret proto-oncogene	11.0	Publications
16	ALPP	alkaline phosphatase, placental	11.0	Publications
17	CALCA	calcitonin-related polypeptide alpha	11.0	Publications
18	SLPI	secretory leukocyte peptidase inhibitor	11.0	Publications
19	ACP5	acid phosphatase 5, tartrate resistant	11.0	Publications
20	PRKAR1A	protein kinase, cAMP-dependent, regulatory, type I, alpha	11.0	Publications
21	CHGA	chromogranin A (parathyroid secretory protein 1)	11.0	Publications
22	TNFRSF11B	tumor necrosis factor receptor superfamily, member 11b	11.0	Publications
23	PTHLH	parathyroid hormone-like hormone	11.0	Publications
24	EPO	erythropoietin	11.0	Publications
25	CD36	CD36 molecule (thrombospondin receptor)	11.0	Publications
26	PTH1R	parathyroid hormone 1 receptor	11.0	Publications
27	KL	klotho	11.0	Publications
28	IGFBP1	insulin-like growth factor binding protein 1	11.0	Publications
29	PAX5	paired box 5	11.0	Publications
30	B2M	beta-2-microglobulin	11.0	Publications
31	CDKN1B	cyclin-dependent kinase inhibitor 1B (p27, Kip1)	11.0	Publications
32	ALB	albumin	11.0	Publications
33	GCM2	glial cells missing homolog 2 (Drosophila)	11.0	Publications
34	PDLIM3	PDZ and LIM domain 3	11.0	Publications
35	CARS	cysteinyl-tRNA synthetase	11.0	Publications
36	GC	group-specific component (vitamin D binding protein)	11.0	Publications
37	SCT	secretin	11.0	Publications
38	SPG7	spastic paraplegia 7 (pure and complicated autosomal recessive)	11.0	Publications
39	BMP7	bone morphogenetic protein 7	11.0	Publications
40	KCNQ1	potassium voltage-gated channel, KQT-like subfamily, member 1	11.0	Publications
41	TGFA	transforming growth factor, alpha	11.0	Publications
42	GHRL	ghrelin/obestatin prepropeptide	11.0	Publications
43	POMC	proopiomelanocortin	11.0	Publications
44	TNFSF11	tumor necrosis factor (ligand) superfamily, member 11	11.0	Publications
45	NF1	neurofibromin 1	11.0	Publications
46	VWF	von Willebrand factor	11.0	Publications
47	GHR	growth hormone receptor	11.0	Publications
48	PRL	prolactin	11.0	Publications
49	CCND1	cyclin D1	11.0	Publications
50	IGF1	insulin-like growth factor 1 (somatomedin C)	11.0	Publications

Pathways related to hyperparathyroidism according to GeneDecks:

(show top 50)    (show all 101)

id	Pathway	Score	Top Affiliating Genes
1	Transcription Role of VDR in regulation of genes involved in osteoporosis10	10.7	VDR, BGLAP, IL6, IGF1, CALCA, TNF
2	Transcription_Role of VDR in regulation of genes involved in osteoporosis41	10.6	RUNX2, COL1A1, CYP27B1, PTH1R, PTH, TNFSF11
3	Class B/2 (Secretin family receptors)38	10.3	WNT3, PTHLH, PTH2R, PTH1R, PTH, GHRH
4	Actin-Based Motility by Rho Family GTPases36	10.1	BMP7, IL2, FGF23, IGF1, GH1, GHRH
5	Akt Signaling36	9.6	CXCL12, TNFSF11, TNF, IGF1R, CCND1, CCL27
6	Breast Cancer Regulation by Stathmin136	9.5	TGFA, GHRH, BMP7, IGF1R, FGF23, FGF2
7	Cytokine-cytokine receptor interaction20	9.4	KITLG, EPO, CSF3, CXCL12, PRL, EGFR
8	14-3-3 Induced Intracellular Signaling36	9.2	IGF1, IGF1R, KITLG, BMP7, FGF2, FGF23
9	eNOS Signaling36	9.1	GH1, BMP7, NOS3, FGF23, PRKAR1A, KITLG
10	NF-KappaB (p50-p65) Pathway36	9.1	FGFR1, CXCL12, PRKAR1A, TGFA, EGFR, IGF1
11	ERK5 Signaling36	9.1	FGFR1, BMP7, FGF23, GH1, CXCL12, TGFA
12	PPAR Pathway36	8.8	GH1, TNF, EGFR, IGF1, IGF2, KITLG
13	NF-KappaB Family Pathway36	8.8	FGF23, FGF2, BMP7, KITLG, EGFR, IL2
14	Rac1 Pathway36	8.8	FGF2, FGF23, FGFR1, IL2, IL6, IGF1R
15	Prostate cancer20	8.6	CDKN1B, INS, FGFR1, CCND1, IGF1R, IGF1
16	JNK Pathway36	8.6	KITLG, BMP7, FGF2, GHRH, CXCL12, CEBPB
17	ERK Signaling36	8.6	TNFSF11, GHRH, CAPN2, IGF2, IGF1R, PLCB3
18	CREB Pathway36	8.5	IGF1, GH1, GHRH, PLCB3, PRKAR1A, IGF2
19	Estrogen Pathway36	8.5	TGFA, GHRH, NOS3, CXCL12, PRKAR1A, IL6
20	ILK Signaling36	8.4	FGF23, CXCL12, TGFA, KITLG, IGF1, IGF1R
21	Nanog in Mammalian ESC Pluripotency36	8.4	IGF2, FGF2, WNT3, CXCL12, TGFA, EGFR
22	Nuclear Receptor Activation by Vitamin-A36	8.4	IGF2, FGF23, KITLG, BMP7, CXCL12, TGFA
23	eIF2 Pathway36	8.3	CXCL12, TGFA, IGF2, IL2, EGFR, GHRH
24	TGF-Beta Pathway36	8.3	IGF1, GH1, GHRH, EGFR, BAX, IGF2
25	Telomerase Components in Cell Signaling36	8.3	FGF23, FGFR1, IL2, IGF1R, IGF2R, IGF1
26	p70S6K Signaling36	8.3	GHRH, EGFR, TGFA, IGF2R, CXCL12, GH1
27	Renin-Angiotensin Pathway36	8.3	IL2, GH1, IGF1R, IL6, IGF2R, BMP7
28	Rap1 Pathway36	8.2	KITLG, BMP7, FGF2, FGF23, FGFR1, IL2
29	PTEN Pathway36	8.2	FGF23, IGF1R, IGF2R, GH1, GHRH, TP53
30	Activation of PKC through GPCR36	8.1	KITLG, BMP7, FGF2, FGF23, IL2, IL6
31	GSK3 Signaling36	8.0	IGF1R, IL6, IL2, FGFR1, FGF23, FGF2
32	Pathways in cancer20	8.0	IGF1R, WNT3, TGFA, EGFR, CTNNB1, TP53
33	Pancreatic Adenocarcinoma36	7.9	KITLG, BRCA2, BMP7, CXCL12, CDKN1A, CDKN2C
34	MAPK Family Pathway36	7.8	CCL27, EGFR, TNF, GHRH, GH1, IGF1
35	GPCR Pathway36	7.8	CXCL12, IGF1R, IGF2, IGF1, GH1, GHRH
36	JAK-STAT Pathway36	7.8	EPO, IL2, IGF1, CXCL12, PRL, TGFA
37	Apoptotic Pathways in Synovial Fibroblasts36	7.7	EGFR, TNF, TP53, GHRH, GH1, IGF1
38	DHA Signaling36	7.5	IGF1R, KITLG, BAX, IGF2R, IL6, IL2
39	Rho Family GTPases36	7.5	TNFSF11, GHRH, COL1A1, TGFA, BMP7, CXCL12
40	Tec Kinases Signaling36	7.4	EGFR, TNF, GHRH, GH1, IGF1, IGF2
41	MAPK Signaling36	7.3	COL1A1, TGFA, PLCB3, EGFR, PRKAR1A, IL2
42	PAK Pathway36	7.2	IGF1, IGF2, IGF2R, IGF1R, CCL27, IL6
43	Mitochondrial Apoptosis36	7.1	CXCL12, TGFA, EGFR, TP53, GHRH, GH1
44	p53 Mediated Apoptosis36	7.1	BAX, FGF2, FGF23, FGFR1, IL2, IL6
45	Antioxidant Action of Vitamin-C36	6.9	CCL27, IL6R, IL6, IL2, FGF23, IGF1R
46	Cellular Apoptosis Pathway36	6.9	IGF2, TGFA, EGFR, TNF, TP53, GHRH
47	p38 Signaling36	6.7	KITLG, GH1, GHRH, IGF1R, TP53, TNFSF11
48	Molecular Mechanisms of Cancer36	6.5	CXCL12, TGFA, EGFR, COL1A1, PLCB3, TNFSF11
49	Development_Hedgehog and PTH signaling pathways in bone and cartilage development41	INF	PRKAR1A, PLCB3, COL1A1, PTHLH, PTH1R, PTH
50	Development Hedgehog and PTH signaling pathways in bone and cartilage development10	INF	VDR, BGLAP, CCND1, , GNAS, TNFSF11

Compounds related to hyperparathyroidism according to GeneDecks:

(show top 50)    (show all 511)

id	Compound	Score	Top Affiliating Genes
1	25-hydroxyvitamin d32	10.3	GC, VDR, BGLAP, PAX5, SCG5, LEP
2	carbohydrates32	10.2	SELE, FGF2, CCK, F10, GHR, TF
3	ly29400232	10.2	RET, SELE, LEP, CDKN1B, FGF2, IL6
4	sodium32 18	10.8	LRP2, SGCB, KCNQ1, SCT, LBR, B2M
5	vitamin b1232	9.6	LRP2, VWF, PCNA, B2M, GPT, IGFBP3
6	rosiglitazone32 9 18 9	12.6	SELE, SERPINE1, CDKN1A, CD36, INS, IL6
7	c-peptide32	9.5	SCT, LEP, CCK, IGF2, IGFBP2, GHR
8	raloxifene32 9 9	11.5	VWF, SERPINE1, VDR, BGLAP, PAX5, CD36
9	tgf beta132	9.4	KITLG, SERPINE1, BMP7, CDKN1A, CD36, CDKN1B
10	triiodothyronine32	9.4	LEP, IGFBP1, IGF2, IGFBP3, IGFBP4, IGF1
11	gold32	9.4	KITLG, BRCA2, BMP7, SCT, CHGA, LBR
12	vitamin a32 9 18 9	12.3	LRP2, RET, VWF, GC, VDR, LEP
13	simvastatin32 34 42 9 18 9	14.2	KITLG, VWF, SELE, SERPINE1, BGLAP, PAX5
14	dehydroepiandrosterone sulfate32	9.1	PAX5, LEP, INS, IGFBP1, IGF2, IGFBP3
15	rapamycin32 42	10.1	KITLG, INS, IL2, FBXO32, IGF1R, IGF2
16	bromodeoxyuridine32	9.1	KITLG, PCNA, BMP7, CHGA, LBR, CDKN1A
17	nifedipine32 9 9	10.9	SELE, SERPINE1, VIP, BGLAP, LEP, CHGA
18	glycerol32 9 18 9	11.8	VWF, PCNA, LEP, CFTR, CD36, MIP
19	h2o232	8.8	SGCB, KITLG, VWF, VIP, BRCA2, BGLAP
20	estrone32 9 18 9	11.8	BGLAP, LEP, IGFBP1, IGF2, IGFBP2, IGFBP3
21	epinephrine32 9 18 9	11.8	KITLG, SELE, VIP, KCNQ1, SCT, LEP
22	caffeine32 34 9 18 9	12.7	PCNA, VIP, VDR, BGLAP, CHGA, CFTR
23	mitomycin c32	8.7	VWF, PCNA, BRCA2, CFTR, FGF2, IGF1R
24	dhea32	8.6	LEP, INS, IGFBP5, IGFBP1, IGF2, IGFBP2
25	acetylcholine32 9 18 9	11.6	SGCB, VWF, VIP, SCT, LEP, CHGA
26	imatinib32 34 9 9	11.5	RET, KITLG, VIP, CDKN1A, CDKN1B, FGFR1
27	methotrexate32 34 42 9 9	12.3	KITLG, PCNA, SELE, SERPINE1, BRCA2, LEP
28	norepinephrine32 9 18 9	11.2	KITLG, VWF, SELE, VIP, SCT, LEP
29	thyroxine32 18	8.5	LRP2, VWF, PCNA, GC, VIP, VDR
30	adenylate32	7.3	SGCB, KITLG, VWF, GC, SELE, SERPINE1
31	alanine32	7.3	RET, KITLG, VWF, PCNA, SELE, VIP
32	glutamine32	7.2	VWF, PCNA, VIP, BRCA2, VDR, SCG5
33	lactate32	7.0	KITLG, VWF, PCNA, SELE, VIP, CHGA
34	actinomycin d32	6.6	KITLG, SELE, SERPINE1, VDR, BAX, CFTR
35	tamoxifen32 34 9 9	8.5	PCNA, SELE, BRCA2, VDR, BGLAP, LEP
36	thymidine32 18	INF	KITLG, PCNA, VIP, BRCA2, VDR, BMP7
37	hydrocortisone32 9 9	INF	KITLG, , BGLAP, CD36, INS, FGF2
38	testosterone32 9 18 9	INF	RET, SGCB, KITLG, PCNA, GC, SELE
39	progesterone32 42 9 18 9	INF	PCNA, BRCA2, BMP7, , CHGA, CEBPB
40	creatinine32	INF	KITLG, VWF, PCNA, GC, SELE, VDR
41	glutamate32	INF	PCNA, GC, VIP, VDR, SCG5, LEP
42	phosphatidylinositol32	INF	RET, KITLG, BRCA2, LEP, BAX, CEBPB
43	vitamin d32	INF	LRP2, LRP5, GC, SERPINE1, VDR, BMP7
44	ibmx32	INF	SGCB, VIP, SCT, CFTR, INS, FGF2
45	cysteine32	INF	SGCB, PCNA, VDR, BGLAP, KCNQ1, SCG5
46	gnrh32	INF	KITLG, SERPINE1, , LEP, CFTR, KAL1
47	pd 98,05932	INF	RET, KITLG, SERPINE1, SCT, LEP, BAX
48	cholesterol32 9 18 9	INF	LRP2, LRP5, KITLG, VWF, GC, SELE
49	calcium32 9 18 9	INF	LRP5, KL, SGCB, KITLG, VWF, GCM2
50	zoledronic acid32	INF	BGLAP, PAX5, CD36, IL2, , ALPP

Cellular components related to hyperparathyroidism according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	basolateral plasma membrane	GO:016323	10.1	CXADR, TGFA, EGFR, PTH1R, IL6R, CFTR
2	insulin-like growth factor binding protein complex	GO:016942	10.0	IGFBP5, IGFBP3, IGF1
3	secretory granule	GO:030141	9.9	POMC, TF, GHRL, INS, CHGA, SCG5
4	extracellular region	GO:005576	INF	ADIPOQ, EPO, GAST, ADM, KL, IL2
5	extracellular space	GO:005615	INF	FGF23, IL2, IL6, IL6R, CCL27, CCK

Biological processes related to hyperparathyroidism according to GeneDecks:

(show top 50)    (show all 60)

id	Name	GO ID	Score	Top Affiliating Genes
1	bone resorption	GO:045453	10.8	ACP5, CTNNB1, PTH1R, PTH, TNFSF11
2	positive regulation of vitamin D 24-hydroxylase activity	GO:010980	10.8	VDR, FGF23, CYP27B1
3	response to estrogen stimulus	GO:043627	10.8	EPO, CYP27B1, TNFRSF11B, GHRL, CCND1, BGLAP
4	positive regulation of osteoblast differentiation	GO:045669	10.6	IGF1, IL6R, IL6, MEN1, FGF2, CEBPB
5	monocyte chemotaxis	GO:002548	10.6	TNFSF11, CALCA, IL6R, IL6
6	regulation of glucose metabolic process	GO:010906	10.6	ADIPOQ, IGFBP4, IGFBP3, IGFBP5
7	positive regulation of tyrosine phosphorylation of Stat5 protein	GO:042523	10.5	EPO, GHR, GH1, IGF1, IL2
8	MAPK cascade	GO:000165	10.5	TGFA, EGFR, NF1, TNF, MEN1, FGFR1
9	positive regulation of cAMP biosynthetic process	GO:030819	10.5	ADM, PTHLH, PTH, GHRH, CALCA
10	aging	GO:007568	10.5	EPO, ADM, NOS3, PTH1R, CALCA, IGFBP2
11	skeletal system development	GO:001501	10.4	TNFRSF11B, PTH, PTH1R, PTHLH, COL1A1, IGF1
12	positive regulation of tyrosine phosphorylation of Stat3 protein	GO:042517	10.4	GHR, GH1, IL6R, IL6, LEP
13	negative regulation of smooth muscle cell migration	GO:014912	10.4	ADIPOQ, IGFBP3, IGFBP5, SERPINE1
14	organ regeneration	GO:031100	10.4	ADM, CXCL12, CCND1, CDKN1A, BAAT, LRP2
15	defense response to Gram-positive bacterium	GO:050830	10.3	ACP5, TNF, IL6R, IL6, CD36
16	negative regulation of osteoblast differentiation	GO:045668	10.3	TNF, IGFBP5, MEN1, FGFR1, FGF23, LRP5
17	positive regulation of insulin-like growth factor receptor signaling pathway	GO:043568	10.3	GHRH, GH1, IGF1, IGFBP4, IGFBP3, IGFBP5
18	G-protein coupled receptor signaling pathway	GO:007186	10.3	SST, PLCB3, CXCL12, GAST, PTH2R, PTH1R
19	female pregnancy	GO:007565	10.2	ADM, NPPA, PRL, PTHLH, GNAS, IGFBP2
20	positive regulation of MAP kinase activity	GO:043406	10.2	EGFR, TNFSF11, TNF, GH1, FGFR1, KITLG
21	cell-cell signaling	GO:007267	10.2	ADM, POMC, SST, PTHLH, PTH, GHRH
22	response to mechanical stimulus	GO:009612	10.2	SOST, CXCL12, NOS3, TNF, IGFBP2, BGLAP
23	response to estradiol stimulus	GO:032355	10.2	NOS3, GC, BRCA2, VDR, IGFBP2, GH1
24	response to glucocorticoid stimulus	GO:051384	10.2	BGLAP, IL6, IGFBP2, GHR, TNF, ADM
25	response to hyperoxia	GO:055093	10.2	EPO, NOS3, CDKN1A, SERPINE1
26	regulation of blood pressure	GO:008217	10.1	NPPA, POMC, NOS3, CALCA, CHGA, LEP
27	positive regulation of MAPK cascade	GO:043410	10.0	IGF1, IGFBP4, IGFBP3, IGF2, IL6R, IL6
28	positive regulation of protein kinase B signaling cascade	GO:051897	10.0	EGFR, TNFSF11, TNF, F10, IGF1, IGF2
29	positive regulation of DNA replication	GO:045740	10.0	EPO, EGFR, IGF1, IGF1R, INS, KITLG
30	positive regulation of glycogen biosynthetic process	GO:045725	10.0	PTH, IGF1, IGF2, INS
31	positive regulation of mitosis	GO:045840	9.9	TGFA, TNF, IGF1, IGF2, INS, LRP5
32	response to hypoxia	GO:001666	9.9	ADIPOQ, ADM, CXCL12, TH, NF1, NOS3
33	response to drug	GO:042493	9.8	SST, CTNNB1, NOS3, ABCB1, TGFA, SLC6A11
34	negative regulation of cell growth	GO:030308	9.6	NPPA, WT1, CYP27B1, TP53, FGF2, CDKN1B
35	insulin-like growth factor receptor signaling pathway	GO:048009	9.5	GHR, IGF1, IGF2R, IGF1R
36	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.5	IGF1, GH1, GHR, TP53, ADIPOQ, IGF2
37	insulin receptor signaling pathway	GO:008286	9.4	IGF2, IGF1R, IGFBP1, FGFR1, FGF23, FGF2
38	negative regulation of transcription, DNA-dependent	GO:045892	9.4	TNF, CTNNB1, WT1, RUNX2, ADIPOQ, TP53
39	response to gamma radiation	GO:010332	9.3	TP53, TRIM13, MEN1, BAX, BRCA2
40	anti-apoptosis	GO:006916	9.3	TGFA, NOS3, TNF, GHRL, IGF1, IGF1R
41	positive regulation of transcription from RNA polymerase II promoter	GO:045944	9.3	IGF1, TP53, TNF, TNFSF11, PTH, CTNNB1
42	response to salt stress	GO:009651	9.2	EPO, TNF, TP53, BAX
43	blood coagulation	GO:007596	9.1	NOS3, COL1A1, TF, PRKAR1A, CXADR, TP53
44	negative regulation of cell proliferation	GO:008285	9.0	VDR, TNF, PTH1R, PTHLH, CYP27B1, SST
45	positive regulation of transcription, DNA-dependent	GO:045893	8.8	TP53, TNF, CTNNB1, COL1A1, WT1, SOST
46	signal transduction	GO:007165	8.7	TG, EGFR, NR1I3, TNFRSF11B, TRIM13, PRKAR1A
47	positive regulation of apoptotic process	GO:043065	8.7	NF1, NOS3, CTNNB1, TNF, TP53, IGFBP3
48	negative regulation of apoptotic process	GO:043066	8.5	GHRL, TP53, TNF, WT1, EGFR, CXCL12
49	positive regulation of cell proliferation	GO:008284	8.2	IGF2, IGF1, GHRH, PTH1R, PTHLH, EGFR
50	ossification	GO:001503	INF	RUNX2, SOST, EGFR, TNFSF11, CASR,

Molecular functions related to hyperparathyroidism according to GeneDecks:

(show all 9)

id	Name	GO ID	Score	Top Affiliating Genes
1	receptor binding	GO:005102	9.9	ADM, NPPA, POMC, CXCL12, CXADR, CALCA
2	peptide hormone receptor binding	GO:051428	9.9	NPPA, PTHLH, PTH, LEP
3	cytokine activity	GO:005125	9.6	ADIPOQ, CSF3, TNFSF11, TNFRSF11B, TNF, IL6
4	protease binding	GO:002020	9.5	CST3, TNF, TP53, INS, BRCA2, SERPINE1
5	insulin-like growth factor I binding	GO:031994	9.4	IGFBP3, IGFBP2, IGF1R, IGFBP6, IGFBP5
6	insulin-like growth factor binding	GO:005520	9.3	IGFBP4, IGFBP3, IGF2R, IGF1R, IGFBP1
7	hormone activity	GO:005179	9.2	PTHLH, SST, TTR, TG, PRL, POMC
8	growth factor activity	GO:008083	9.0	IGF1, GH1, TGFA, DKK1, CXCL12, CSF3
9	protein binding	GO:005515	INF	SPINK1, TF, DKK1, PRKAR1A, CXADR, SOST